INVO Fertility reports 116% revenue growth to $6.5M in FY2024; adjusted EBITDA improves to $(2.2)M

INVO Fertility, Inc.

2025-Q1 EPS reported -$12.53 revenue$1,637,185

Q4 2024 revenue $1.69M (+22% YoY); full-year revenue $6.53M (+116% YoY).
Net loss widened to $(9.1)M in FY2024 from $(8.0)M, driven by NAYA Therapeutics merger costs.
Adjusted EBITDA improved to $(2.2)M in FY2024 from $(4.9)M in FY2023.
Company announced intent to divest majority stake in NAYA TX to refocus on fertility clinic operations.
Management cites declining U.S. fertility rate and rising ART demand as expansion catalysts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.